Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing a first-in-class approach to treat human carcinomas of high unmet medical needs. Based in San Francisco Bay Area, the company has raised $105 million to date.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/12/25 | $35,000,000 | Series D |
Canaan Partners Cenova Capital RA Capital Management  | undisclosed |
